Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer

Nutrition and Cancer

Volumn 62, Issue 6, 2010, Pages 795-801

  Tokalov, Sergey V ^a   Abramyuk, Andrij M ^a   Abolmaali, Nasreddin D ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GENISTEIN; PACLITAXEL; PROTEIN P53; QUERCETIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL KILLING; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MITOSIS; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; GENISTEIN; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955000112     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581003605912     Document Type: Article

References (30)

1. Bayman NA, Blackhall F, Jain P, Lee L, Thatcher N et al.: Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 9, 92-101, 2008.
2. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, and Shishodia S: Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 102, 580-592, 2007.
3. Viktorsson K, De Petris L, amd Lewensohn R: The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331, 868-880, 2005.
4. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, et al.: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18, 705-719, 2001. (Pubitemid 33040631)
5. Blagosklonny MV: Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21, 6249-6254, 2002.
6. Kale A, Gawande S, and Kotwal S: Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res 22, 567-577, 2008.
7. Tokalov SV, Kind B, Wollenweber E, and Gutzeit HO: Biological effects of epicuticular flavonoids from Primula denticulata on human leukemia cells. J Agric Food Chem 52, 239-245, 2004.
8. Ludwig-Muller J, Tokalov SV, Franz A, and Gutzeit HO: Quercetin metabolism in vital and apoptotic human leukaemia cells. Biol Chem 386, 279-283, 2005.
9. Tokalov SV, Henker Y, Schwab P, Metz P, and Gutzeit HO: Toxicity and cell cycle effects of synthetic 8-prenylnaringenin and derivatives in human cells. Pharmacology 71, 46-56, 2004.
10. Kuzumaki T, Kobayashi T, and Ishikawa K: Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem Biophys Res Commun 251, 291-295, 1998.
11. Zhang Q, Zhao XH, and Wang ZJ: Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol 46, 2042-2053, 2008.
12. Shukla S and Gupta S: Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6, 1102-1114,2007.
13. Zou H, Zhan S, and Cao K: Apoptotic activity of genistein on human lung adenocarcinoma SPC-A-1 cells and preliminary exploration of its mechanisms using microarray. Biomed Pharmacother 62, 583-589, 2008.
14. Ranelletti FO, Ricci R, LaroccaLM, MaggianoN, Capelli A, et al.: Growth- inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. Int J Cancer 50, 486-492, 1992.
15. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, et al.: Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 29, 92-102, 2000.
16. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, et al.: Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77, 875-882, 2003.
17. Tokalov SV, Pieck S, and Gutzeit HO: Varying responses of human cells with discrepant p53 activity to ionizing radiation and heat shock exposure. Cell Prolif 40, 24-37, 2007.
18. Un F: G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers. Anticancer Drugs 18, 411-417, 2007.
19. Cummings J, Anderson L, Willmott N, and Smyth JF: The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 27, 532-535, 1991.
20. Potter AJ and Rabinovitch PS: The cell cycle phases of DNA damage and repair initiated by topoisomerase Il-targeting chemotherapeutic drugs. Mutat Res 572, 27-44, 2005.
21. Bhalla KN: Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075-9086, 2003.
22. Merten JHA, Schwab P, Frohlich R, Tokalov SV, Gutzeit HO, et al.: A concise sultone routine to haighly oxygenated 1,10-seco-eudesmanolides- enantioselective total synthesis on the antileukemic sesquiterpene lactones (-)-eriolanin and (-)-eriolangin. Eur J Org Chem 5, 1144-1161, 2006.
23. Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E et al.: Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 27, 4402-4410, 2008.
24. Viallet J, Tsao MS, and Gallant G: Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines. Lung Cancer 15, 93-101, 1996.
25. Liu LZ, Fang J, Zhou Q, Hu X, Shi X, et al.: Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 68, 635-643, 2005.
26. Hermann RM, Fest J, Christiansen H, Hille A, Rave-Frank M, et al.: Ra- diosensitization dependent on p53 function in bronchial carcinoma cells by the isoflavone genistein and estradiol in vitro. Strahlenther Onkol 183, 195-202, 2007.
27. Nitzsche A, Tokalov SV, Gutzeit HO, and Ludwig-Muller J: Chemical and biological characterization of cinnamic acid derivatives from cell cultures of lavender (Lavandula officinalis) induced by stress and jasmonic acid. J Agric Food Chem 52, 2915-2923, 2004.
28. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, et al.: Clinical characteristics and pharmacokinetics of purified soy isoflavones: single- dose administration to healthy men. Am J Clin Nutr 75, 126-136, 2002.
29. Adlercreutz H, Markkanen H, and Watanabe S: Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342, 1209-1210, 1993.
30. King RA and Bursill DB: Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67, 867-872, 1998.